» Articles » PMID: 36438034

SARS-CoV-2 Variants: Impact on Biological and Clinical Outcome

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that was first identified in December 2019, in Wuhan, China was found to be the etiological agent for a novel respiratory infection that led to a Coronavirus Induced Disease named COVID-19. The disease spread to pandemic magnitudes within a few weeks and since then we have been dealing with several waves across the world, due to the emergence of variants and novel mutations in this RNA virus. A direct outcome of these variants apart from the spike of cases is the diverse disease presentation and difficulty in employing effective diagnostic tools apart from confusing disease outcomes. Transmissibility rates of the variants, host response, and virus evolution are some of the features found to impact COVID-19 disease management. In this review, we will discuss the emerging variants of SARS-CoV-2, notable mutations in the viral genome, the possible impact of these mutations on detection, disease presentation, and management as well as the recent findings in the mechanisms that underlie virus-host interaction. Our aim is to invigorate a scientific debate on how pathogenic potential of the new pandemic viral strains contributes toward development in the field of virology in general and COVID-19 disease in particular.

Citing Articles

Effect of Exportin 1/XPO1 Nuclear Export Pathway Inhibition on Coronavirus Replication.

Rahman M, Estifanos B, Glenn H, Gutierrez-Jensen A, Kibler K, Li Y Viruses. 2025; 17(2).

PMID: 40007039 PMC: 11860411. DOI: 10.3390/v17020284.


COVID-19 symptom severity and duration among outpatients, July 2021-May 2023: The PROTECT observational study.

Vashi B, Pettrone K, Wilson C, Chenoweth J, Brandsma J, Gregory M PLoS One. 2025; 20(2):e0314518.

PMID: 39982872 PMC: 11844841. DOI: 10.1371/journal.pone.0314518.


Mice carrying the full-length human immunoglobulin loci produce antigen-specific human antibodies with the lambda light chain.

Shimoya K, Moriwaki T, Kazuki K, Okada A, Baba S, Masuda Y iScience. 2025; 27(12):111258.

PMID: 39758990 PMC: 11700626. DOI: 10.1016/j.isci.2024.111258.


SARS-CoV-2 strains and clinical profiles of COVID-19 patients in a Southern Brazil hospital.

Fam B, Cadore N, Sbruzzi R, Feira M, Giudicelli G, de Almeida L Front Immunol. 2025; 15:1444620.

PMID: 39744633 PMC: 11688617. DOI: 10.3389/fimmu.2024.1444620.


Late Recurrence of C3 Glomerulopathy After SARS-CoV-2 Infection in a Long-Term Kidney Transplant Recipient: A Case Report.

Bartoli G, Dello Strologo A, Arena M, Galeandro E, Ferro M, Diomedi-Camassei F Am J Case Rep. 2024; 25:e944208.

PMID: 39628044 PMC: 11627295. DOI: 10.12659/AJCR.944208.


References
1.
Greenhalgh T, Jimenez J, Prather K, Tufekci Z, Fisman D, Schooley R . Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet. 2021; 397(10285):1603-1605. PMC: 8049599. DOI: 10.1016/S0140-6736(21)00869-2. View

2.
Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

3.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

4.
Gravagnuolo A, Faqih L, Cronshaw C, Wynn J, Klapper P, Wigglesworth M . High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern. EBioMedicine. 2021; 70:103540. PMC: 8358312. DOI: 10.1016/j.ebiom.2021.103540. View

5.
Bruijns B, Folkertsma L, Tiggelaar R . FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances. Biosens Bioelectron X. 2022; 11:100158. PMC: 9122839. DOI: 10.1016/j.biosx.2022.100158. View